AI English summary of an SEC filing — figures as filed
Elevance Health ELVThe company said operating revenue for Q1 2025 was $48.8 billion, up 15.4% from 1Q 2024, and adjusted operating gain rose 4.1% to $3.3 billion.
Key points
AI summaryThe company said operating revenue for Q1 2025 was $48.8 billion, up 15.4% from 1Q 2024, and adjusted operating gain rose 4.1% to $3.3 billion.
Elevance Health said diluted EPS for Q1 2025 was $9.61 and adjusted diluted EPS was $11.97. It also reaffirmed its FY 2025 adjusted diluted EPS outlook of $34.15 to $34.85.
The company said its benefit expense ratio for Q1 2025 was 86.4%, up 80 basis points year over year, reflecting higher Medicaid medical cost trend. It said its operating expense ratio was 10.9%, an improvement of 70 basis points.
Elevance Health said operating cash flow for Q1 2025 was $1.0 billion, a decrease of approximately $1.0 billion year over year. In the same quarter, it repurchased 2.2 million shares at $880 million and paid $386 million in dividends.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Q1 Operating Revenue $48.8 billion, Adjusted Operating Gain $3.3 billion
The company said operating revenue for Q1 2025 was $48.8 billion, up 15.4% from 1Q 2024, and adjusted operating gain rose 4.1% to $3.3 billion.
Source · Based on the filing body and exhibits
Diluted EPS $9.61, Adjusted $11.97, Full-Year Outlook Reaffirmed
Elevance Health said diluted EPS for Q1 2025 was $9.61 and adjusted diluted EPS was $11.97. It also reaffirmed its FY 2025 adjusted diluted EPS outlook of $34.15 to $34.85.
Source · Based on the filing body and exhibits
Benefit Expense Ratio 86.4%, Operating Expense Ratio 10.9%
The company said its benefit expense ratio for Q1 2025 was 86.4%, up 80 basis points year over year, reflecting higher Medicaid medical cost trend. It said its operating expense ratio was 10.9%, an improvement of 70 basis points.
Source · Based on the filing body and exhibits
Operating Cash Flow $1.0 billion, Share Repurchases $880 million
Elevance Health said operating cash flow for Q1 2025 was $1.0 billion, a decrease of approximately $1.0 billion year over year. In the same quarter, it repurchased 2.2 million shares at $880 million and paid $386 million in dividends.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…